Τίτλος: IMI2-2016-10-01 Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
Πρόγραμμα: Horizon 2020
Τύπος πρόσκλησης: Joint Undertaking (JU)
Φορέας Διαχείρισης: Innovative Medicines Initiative (IMI)
Δράση: Innovative Medicines Initiative 2 (IMI2)
Call ID: IMI2-2016-10-01
Action Type: RIA – Research and Innovation Actions
Προθεσμία first stage: 28/3/2017 17:00 Brussels Time / 2nd stage Deadline: 14 September 2017 17:00:00 Brussels Time
Η “Innovative Medicines Initiative” (IMI) είναι η μεγαλύτερη Ευρωπαϊκή πρωτοβουλία σύμπραξης δημόσιου – ιδιωτικού τομέα με σκοπό να επιταχύνει την δημιουργία καλύτερων και ασφαλέστερων φαρμάκων.
Συνοπτικά για την Πρόσκληση
Diabetes represents an increasing global healthcare challenge. Controlling blood glucose is a cornerstone in diabetes management aiming to reduce the increased morbidity and mortality associated with this disease. However, only around 50% of patients achieve accepted international glycaemic targets.
Hypoglycaemia is common, and the importance of hypoglycaemia as a major concern for both healthcare professionals and patients is reflected by its impact on intrusions into daily living as well as serious consequences including hospitalisation and mortality. Hypoglycaemia and the fear of hypoglycaemia represent a recognised and measurable contributor to the burden of disease for people afflicted by diabetes, as well as their families, friends, and other parties – also known as ‘The Greater Patient .
Thus, hypoglycaemia is an important clinical issue for many people with diabetes, and it constitutes a major concern for patients on glucose lowering treatment regimens, who face the daily challenge of achieving accepted glucose targets safely, without increasing the risk of hypoglycaemia.
In recent years we have seen an increasing number of phase III clinical trials in type 1 and type 2 diabetes, but despite the improved accuracy of glucose measuring devices and increased patient access to continuous glucose monitoring (CGM) technology, detecting and reliably registering hypoglycaemic events in clinical trials remain a challenge. No approved guidelines or methods for how hypoglycaemia should be measured exist. Regarding hypoglycaemia, detailed monitoring of blood glucose and the recording of daily events, including physical activity and diet, are rarely carried out. Although data on severe and in most cases, symptomatic hypoglycaemia are collected during the trial period, information on other types of hypoglycaemia, particularly asymptomatic as well as episodes wherein patient outcomes are not immediately noticeable is limited. Moreover, people with a past history of severe hypoglycaemia are often excluded from clinical trials and little if any information is routinely collected on other types of pre-trial hypoglycaemia; as a consequence, this type of information is rarely included in post-trial analyses…
|Τμήματα|| Χημείας, Βιολογίας, Πληροφορικής και Τηλεπικοινωνιών, Σχολή Ιατρικής, Οδοντιατρικής, Φαρμακευτικής